These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19686788)

  • 41. Evaluation of the Impact of Codon Optimization and N-Linked Glycosylation on Functional Immunogenicity of Pfs25 DNA Vaccines Delivered by In Vivo Electroporation in Preclinical Studies in Mice.
    Datta D; Bansal GP; Kumar R; Ellefsen B; Hannaman D; Kumar N
    Clin Vaccine Immunol; 2015 Sep; 22(9):1013-9. PubMed ID: 26135972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant poly(N-isopropylacrylamide) generates more efficient monoclonal antibodies against truncated recombinant histidine-rich protein2 of Plasmodium falciparum for malaria diagnosis.
    Verma R; Ravichandran R; Jayaprakash NS; Kumar A; Vijayalakshmi MA; Venkataraman K
    Biotechnol J; 2015 May; 10(5):772-82. PubMed ID: 25641957
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66.
    Carcaboso AM; Hernández RM; Igartua M; Gascón AR; Rosas JE; Patarroyo ME; Pedraz JL
    Int J Pharm; 2003 Jul; 260(2):273-82. PubMed ID: 12842346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.
    Nardin EH; Oliveira GA; Calvo-Calle JM; Wetzel K; Maier C; Birkett AJ; Sarpotdar P; Corado ML; Thornton GB; Schmidt A
    Infect Immun; 2004 Nov; 72(11):6519-27. PubMed ID: 15501783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.
    Qian F; Rausch KM; Muratova O; Zhou H; Song G; Diouf A; Lambert L; Narum DL; Wu Y; Saul A; Miller LH; Long CA; Mullen GE
    Vaccine; 2008 May; 26(20):2521-7. PubMed ID: 18423804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
    Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
    Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
    Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
    N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
    Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.
    Fox CB; Baldwin SL; Duthie MS; Reed SG; Vedvick TS
    AAPS PharmSciTech; 2012 Jun; 13(2):498-506. PubMed ID: 22415641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
    Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
    Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose.
    Kaslow DC; Shiloach J
    Biotechnology (N Y); 1994 May; 12(5):494-9. PubMed ID: 7764708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
    Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
    Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
    Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
    Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.
    Billaud JN; Peterson D; Lee BO; Maruyama T; Chen A; Sallberg M; Garduño F; Goldstein P; Hughes J; Jones J; Milich D
    Vaccine; 2007 Feb; 25(9):1593-606. PubMed ID: 17178179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of vitamin loaded topical liposomal formulation using factorial design approach: drug deposition and stability.
    Padamwar MN; Pokharkar VB
    Int J Pharm; 2006 Aug; 320(1-2):37-44. PubMed ID: 16707237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.